|
|
|
|
|
03.06.26 - 21:12
|
Median Technologies Announces Successful Upsized Capital Increase of € 50 Million (Business Wire)
|
|
|
Not to be published, distributed or disseminated, directly or indirectly, in the United States of America, Australia, Canada, South Africa and Japan
Great Success of the capital increase with €50 million raised from institutional investors and retail.
Global Offering of €40 million was multiple times oversubscribed, demonstrating strong market support.
Full implementation of the Reserved Offering for an additional amount of 10 million euros
Net proceeds will be allocated to the commercial deployment of eyonis® LCS in the U.S. and Europe and advance new clinical indications for eyonis®, Median's proprietary pan-cancer early diagnostics suite
After the transaction, the Company's cash runway is extended until first half-year 2028. The cash runway could be extended to mid-2029, with the full exercise of the warrants issued and outstanding in 2025.
SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News:
Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Comp...
|
|
|
|
|
|
|
03.06.26 - 15:12
|
Abivax: Kurseinbruch trotz Erfolg (GoingPublic)
|
|
|
Bildnachweis: Ralf Geithe – stock.adobe.com, stock3.com. Mit den Phase-3-Daten zu Obefazimod hat Abivax eines der stärksten Wirksamkeitssignale vorgelegt, die bislang bei Colitis ulcerosa beobachtet wurden. Dennoch verlor die Aktie innerhalb […]
Der Beitrag Abivax: Kurseinbruch trotz Erfolg erschien zuerst auf GoingPublic.de....
|
|
|
03.06.26 - 08:54
|
Novo Nordisk Aktie: Tiefere Korrektur im Aufwärtstrend (Aktiencheck)
|
|
|
Paris (www.aktiencheck.de) - Novo Nordisk Aktie: Tiefere Korrektur im Aufwärtstrend
Am Dienstag geriet die Novo Nordisk-Aktie (ISIN: DK0062498333, WKN: A3EU6F, Ticker-Symbol: NOV, NASDAQ Kopenhagen-Symbol: NOVO B) weiter unter Druck und schloss bei 37,16 EUR mit einem Minus von 2,60% direkt am 50er-EMA bei 37,14 EUR, der nun als entscheidende Unterstützung fungiert, wie aus der Veröffentlichung "dailyAKTIEN" der BNP Paribas hervorgeht. [mehr]...
|
|
|
|
|
|
|
|
|
02.06.26 - 22:33
|
Nanobiotix Provides First Quarter 2026 Operational and Financial Update (GlobeNewswire EN)
|
|
|
PARIS and CAMBRIDGE, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today provided an update on operational progress and reported financial results for the first quarter of 2026....
|
|
|
|
|
|
|
|
|
|
|
02.06.26 - 15:57
|
Abivax Crashes Most On Record After Cancer Cases In Trial Data Spooks Wall Street (ZeroHedge)
|
|
|
Abivax Crashes Most On Record After Cancer Cases In Trial Data Spooks Wall Street
French biotech Abivax suffered its largest intraday decline on record after reporting new data on its lead experimental inflammatory bowel disease drug, which showed cancer cases among patients in the clinical trial. The new data certainly point to regulatory headwinds and raise the risk profile for approval.
Abivax's ABTECT maintenance data showed strong efficacy readout, with both once-daily obefazimod doses meeting the primary endpoint at week 44. Clinical remission rates were 50.8% for the 25 mg dose and 51.3% for the 50 mg dose, versus 10.4% for placebo, implying placebo-adjusted remission rates of about 39% to 40% and highly statistically significant results.
The problem for the stock was not efficacy, but safety optics...
Goldman analyst Esah Hayat pointed out that the market was focused not on efficacy but on cancer cases among patients taking the higher doses of obefazimod:
ABTECT maintenance trial out ...
|
|
|
02.06.26 - 15:06
|
Wayleadr Announces Majority Growth Investment to Accelerate Global Expansion (Business Wire)
|
|
|
SAN FRANCISCO--(BUSINESS WIRE)--Wayleadr, the category-defining Arrival Platform transforming how people and vehicles access workplaces and parking, today announced a majority growth investment to accelerate the company's next phase of global expansion.
Founded in 2016 by entrepreneur Garret Flower, Wayleadr pioneered the Arrival Platform category, helping many of the world's leading enterprises modernize parking, workplace access, and visitor management across global portfolios. Today, the platform powers millions of seamless arrivals annually for organizations including OpenAI, Google, Uber, Novartis, Sanofi, Riot Games, and other leading global enterprises.
Under Flower's leadership as Founder & CEO, Wayleadr expanded internationally across 10+ countries, with a strong focus on the US market, becoming one of the most recognized technology platforms in workplace operations.
“This is an important milestone for Wayleadr and a reflection of what the team has built over the past several years,” said ...
|
|
|
02.06.26 - 14:33
|
Inventiva Announces Trading Resumption of its Ordinary Shares on Euronext Paris (GlobeNewswire EN)
|
|
|
Daix (France), New York City (New York, United States), June 2, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the trading resumption of its ordinary shares on the regulated market of Euronext in Paris as from 3:30 p.m. CEST....
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
